The Gut-Brain Axis in Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the myelin sheath that insulates nerve fibres in the central nervous system. This demyelination disrupts nerve signal transmission, causing symptoms ranging from fatigue and numbness to vision loss and impaired mobility. While genetics contribute approximately 30% of MS risk, the rapid increase in global MS incidence points to environmental factors, and the gut microbiome has emerged as a critical piece of the puzzle.

The evidence linking the gut to MS is now substantial. Multiple independent research groups across the International MS Microbiome Study (iMSMS) have confirmed that MS patients harbour a distinct gut microbiome that differs from healthy controls in composition, diversity, and functional capacity.

Key Microbiome Findings in MS

Depleted Protective Bacteria

MS patients consistently show reduced populations of bacteria that produce anti-inflammatory metabolites:

  • Faecalibacterium prausnitzii — the primary butyrate producer in the human gut, reduced in MS compared to controls. Butyrate strengthens the blood-brain barrier and suppresses neuroinflammation
  • Prevotella histicola — when administered to mice with experimental autoimmune encephalomyelitis (the animal model of MS), this species suppressed disease and reduced neuroinflammation
  • Butyricimonas species — another butyrate producer consistently depleted in MS

Enriched Pro-Inflammatory Species

Conversely, several bacterial species are enriched in the MS gut:

  • Akkermansia muciniphila — while generally considered beneficial for metabolic health, in MS it is paradoxically enriched and may contribute to mucus layer degradation and increased gut permeability
  • Methanobrevibacter and Acinetobacter — associated with pro-inflammatory immune responses in MS
The MS microbiome signature is not uniform across all patients. Different MS subtypes (relapsing-remitting, secondary progressive, primary progressive) may have distinct microbial profiles, suggesting that microbiome-based interventions may need to be tailored to disease subtype.

How Gut Bacteria Influence Neuroinflammation

Short-Chain Fatty Acids and the Blood-Brain Barrier

Short-chain fatty acids (SCFAs), particularly butyrate and propionate, play critical roles in maintaining blood-brain barrier integrity and modulating microglial activation in the CNS. When gut-derived SCFA production decreases due to dysbiosis, the blood-brain barrier becomes more permeable to immune cells and inflammatory mediators, potentially accelerating demyelination.

T-Cell Polarisation

Gut bacteria directly influence the balance between pro-inflammatory Th17 cells and anti-inflammatory T-regulatory cells. In MS, this balance is shifted toward Th17 dominance. Th17 cells produce IL-17, which promotes blood-brain barrier breakdown, recruits inflammatory cells into the CNS, and directly damages oligodendrocytes (the cells that produce myelin).

Molecular Mimicry

Certain gut bacterial proteins share structural similarity with myelin proteins. When these bacterial antigens cross a compromised gut barrier and activate the immune system, the resulting antibodies and T-cells may cross-react with myelin in the central nervous system. This molecular mimicry mechanism represents a direct pathway from gut dysbiosis to CNS demyelination.

The Faecal Microbiota Transplant Evidence

Perhaps the most compelling evidence for the gut-MS connection comes from faecal microbiota transplant (FMT) studies. When germ-free mice are colonised with gut bacteria from MS patients, they develop more severe experimental autoimmune encephalomyelitis than mice colonised with bacteria from healthy controls. This demonstrates that the MS-associated microbiome is not merely a passive marker but actively contributes to neuroinflammation.

Small human pilot studies of FMT in MS patients have shown improvements in regulatory T-cell function and reductions in relapse rate, though larger controlled trials are needed before FMT can be recommended as a clinical intervention.

Dietary Approaches for MS Patients

High-Fibre, Plant-Diverse Diet

The most evidence-supported dietary approach for MS involves increasing fibre diversity to restore SCFA production. The Wahls Protocol, developed by Dr. Terry Wahls (who herself has MS), emphasises 9 cups of vegetables and fruits daily, divided into leafy greens, sulphur-rich vegetables, and deeply coloured produce.

Omega-3 Fatty Acids

Omega-3s from fatty fish and fish oil supplements reduce neuroinflammation through their conversion to specialised pro-resolving mediators (SPMs). Observational data suggests that higher omega-3 intake is associated with reduced MS disease activity and slower disability progression.

Vitamin D

Vitamin D deficiency is a well-established risk factor for MS and is associated with increased relapse rate. Vitamin D modulates both gut immune function and the gut microbiome, creating a triangulated relationship between vitamin D status, gut health, and MS activity. Most MS specialists recommend maintaining serum 25(OH)D levels above 40 ng/mL.

Integrating Gut Health Into MS Care

Gut health optimisation should be considered an adjunct to disease-modifying therapy, not a replacement. Practical steps include increasing dietary fibre diversity, maintaining adequate vitamin D levels, incorporating fermented foods, minimising ultra-processed food intake, and monitoring gut symptoms as potential early indicators of disease activity changes. GutIQ can help MS patients systematically track the relationship between gut health and neurological symptom patterns.